Eisai Presents Clinical Study Results of Novel Orexin Receptor Agonist E2086 for Narcolepsy at World Sleep 2025 Eisai Sep 08, 2025 16:49 HKT/SGT Read More
Eisai to Present Latest Data on Lemborexant and Novel Orexin Receptor Agonist E2086 at The World Sleep 2025 Eisai Sep 04, 2025 09:56 HKT/SGT Read More
Eisai Initiated Rolling Supplemental Biologics License Application to the U.S. FDA for LEQEMBI(R) IQLIK(TM) (lecanemab-irmb) as a Subcutaneous Starting Dose for the Treatment of Early Alzheimer's Disease Under Fast Track Status Eisai Sep 03, 2025 10:32 HKT/SGT Read More
Everest Medicines Announces 2025 Interim Results: 'Dual-Engine' Strategy Driving Strong Synergies Between Commercialization and R&D Everest Medicines Limited Sep 01, 2025 21:55 JST Read More
Everest Medicines Announces 2025 Interim Results: 'Dual-Engine' Strategy Driving Strong Synergies Between Commercialization and R&D Everest Medicines Limited Sep 01, 2025 20:55 HKT/SGT Read More
FDA Approves LEQEMBI(R) IQLIK(TM) (lecanemab-irmb) Subcutaneous Injection for Maintenance Dosing for the Treatment of Early Alzheimer's Disease Eisai Sep 01, 2025 12:44 HKT/SGT Read More
Ministry Of Health, Labour and Welfare Grants Orphan Drug Designation in Japan to Anticancer Agent Tazemetostat for Unresectable INI1-Negative Epithelioid Sarcoma Eisai Aug 29, 2025 17:17 HKT/SGT Read More
Modern Dental Group Reports 34.7% Surge in 1H2025 Net Profit Modern Dental Group Limited Aug 29, 2025 09:25 HKT/SGT Read More
Yunkang Group's 2025 Interim Net Loss Narrows, Demonstrating Strong Operational Resilience Yunkang Group Limited Aug 29, 2025 00:02 HKT/SGT Read More